These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 24415460)

  • 21. Human monoclonal antibodies isolated from spontaneous Epstein-Barr virus-transformed tumors of Hu-SPL-SCID mice and specific for fusion protein display broad neutralizing activity toward respiratory syncytial virus.
    Chamat S; Walsh EE; Anderson D; Osta M; Awaraji C; Pan LZ; Ochi J; Shuey S; Brams P
    J Infect Dis; 1999 Aug; 180(2):268-77. PubMed ID: 10395839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune responses to the nonglycosylated ectodomain of respiratory syncytial virus attachment glycoprotein mediate pulmonary eosinophilia in inbred strains of mice with different MHC haplotypes.
    Hancock GE; Tebbey PW; Scheuer CA; Pryharski KS; Heers KM; LaPierre NA
    J Med Virol; 2003 Jun; 70(2):301-8. PubMed ID: 12696122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-resolution epitope mapping for monoclonal antibodies to the structural protein Erns of classical swine fever virus using peptide array and random peptide phage display approaches.
    Lin M; McRae H; Dan H; Tangorra E; Laverdiere A; Pasick J
    J Gen Virol; 2010 Dec; 91(Pt 12):2928-40. PubMed ID: 20810747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-immunization of BALB/c mice with recombinant immunogens containing G protein fragment and chimeric CTL epitope of respiratory syncytial virus induces enhanced cellular immunity and high level of antibody response.
    Fan CF; Mei XG
    Vaccine; 2005 Aug; 23(35):4453-61. PubMed ID: 15935522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein.
    Martínez I; Melero JA
    J Gen Virol; 1998 Sep; 79 ( Pt 9)():2215-20. PubMed ID: 9747731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the antibody specificities of human convalescent-phase sera against the attachment (G) protein of human respiratory syncytial virus: influence of strain variation and carbohydrate side chains.
    Palomo C; Cane PA; Melero JA
    J Med Virol; 2000 Apr; 60(4):468-74. PubMed ID: 10686032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective immune responses induced by the immunization of mice with a recombinant bacteriophage displaying an epitope of the human respiratory syncytial virus.
    Bastien N; Trudel M; Simard C
    Virology; 1997 Jul; 234(1):118-22. PubMed ID: 9234952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of neutralizing affinity-matured human respiratory syncytial virus F binding antibodies in the sub-picomolar affinity range.
    Canziani GA; Melero JA; Lacy ER
    J Mol Recognit; 2012 Mar; 25(3):136-46. PubMed ID: 22407977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sublingual administration of a helper-dependent adenoviral vector expressing the codon-optimized soluble fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in mice.
    Fu YH; Jiao YY; He JS; Giang GY; Zhang W; Yan YF; Ma Y; Hua Y; Zhang Y; Peng XL; Shi CX; Hong T
    Antiviral Res; 2014 May; 105():72-9. PubMed ID: 24560779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus.
    Schuster JE; Cox RG; Hastings AK; Boyd KL; Wadia J; Chen Z; Burton DR; Williamson RA; Williams JV
    J Infect Dis; 2015 Jan; 211(2):216-25. PubMed ID: 24864121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conservation of G-Protein Epitopes in Respiratory Syncytial Virus (Group A) Despite Broad Genetic Diversity: Is Antibody Selection Involved in Virus Evolution?
    Trento A; Ábrego L; Rodriguez-Fernandez R; González-Sánchez MI; González-Martínez F; Delfraro A; Pascale JM; Arbiza J; Melero JA
    J Virol; 2015 Aug; 89(15):7776-85. PubMed ID: 25995258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV.
    Skaricic D; Traube C; De B; Joh J; Boyer J; Crystal RG; Worgall S
    Virology; 2008 Aug; 378(1):79-85. PubMed ID: 18556039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.
    Magro M; Mas V; Chappell K; Vázquez M; Cano O; Luque D; Terrón MC; Melero JA; Palomo C
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3089-94. PubMed ID: 22323598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterisation of mouse monoclonal antibodies targeting linear epitopes on Chikungunya virus E2 glycoprotein.
    Chua CL; Chan YF; Sam IC
    J Virol Methods; 2014 Jan; 195():126-33. PubMed ID: 24134938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus.
    Liu C; Day ND; Branigan PJ; Gutshall LL; Sarisky RT; Del Vecchio AM
    Virol J; 2007 Jul; 4():71. PubMed ID: 17623075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of recombinant metapneumovirus nucleocapsid protein as nucleocapsid-like particles and development of virus-specific monoclonal antibodies.
    Petraitytė-Burneikienė R; Nalivaiko K; Lasickienė R; Firantienė R; Emužytė R; Sasnauskas K; Zvirblienė A
    Virus Res; 2011 Nov; 161(2):131-9. PubMed ID: 21827798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-reactive and group-specific immune responses to a neutralizing epitope of the human respiratory syncytial virus fusion protein.
    Corvaisier C; Bourgeois C; Pothier P
    Arch Virol; 1997; 142(6):1073-86. PubMed ID: 9228999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice.
    Haynes LM; Caidi H; Radu GU; Miao C; Harcourt JL; Tripp RA; Anderson LJ
    J Infect Dis; 2009 Aug; 200(3):439-47. PubMed ID: 19545210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of neutralizing efficacy of monoclonal antibodies specific for 2009 pandemic H1N1 influenza A virus in vitro and in vivo.
    Chen J; Yan B; Chen Q; Yao Y; Wang H; Liu Q; Zhang S; Wang H; Chen Z
    Arch Virol; 2014 Mar; 159(3):471-83. PubMed ID: 24057757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein.
    Elliott MB; Pryharski KS; Yu Q; Boutilier LA; Campeol N; Melville K; Laughlin TS; Gupta CK; Lerch RA; Randolph VB; LaPierre NA; Dack KM; Hancock GE
    J Virol; 2004 Aug; 78(16):8446-54. PubMed ID: 15280453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.